gel-e Inc., announces the issuance of United States Patent Number 10,179,145 by the U.S. Patent and Trademark Office, which broadly claims and discloses uses of the Company’s core technology.
HOLD THE DATE – February 28, 2019 8 am. – 3:00 p.m.
Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!)
8-8:30 Networking and Registration
8:30 – 12:00 p.m. – Program Overviews
12:00 p.m. – 1:00 p.m. – Networking Lunch
1:00 p.m. – 3:00 p.m – 1:1 Meetings with Program Managers*
Agencies represented include:
NSF, NIH NIA, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)
*The program overview will be available by videoconference.
**You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.
PRE-REGISTRATION IS REQUIRED: RSVP by noon 2/26: BHI@BioHealthInnovation.org
After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.
Our National Cancer Institute-University of Maryland (NCI-UMD) Partnership for Integrative Cancer Research reflects the broad interests of our participating NCI and UMD researchers. We are delighted to invite you to our annual NCI-UMD Partnership for Integrative Cancer Research Symposium on Friday, February 8th from 10am-4pm which will take place in Bethesda, Maryland in the John Edward Porter Neuroscience Research Center at the National Institutes of Health, Bldg 35A, Room 620/630. Please register and plan to participate in our October symposium. The final agenda will be announced shortly.
The past decade has seen intensified research collaboration between pharmaceutical companies and academic institutions. Although such partnerships are recognized as a source of innovation and a key pillar to advance science in drug discovery, they are replete with challenges. Despite much anecdotal evidence and debate, fact-based evidence on the nature of these challenges and how to manage them is scarce.
Deloitte has surpassed its peers to become the world’s most valuable professional services brand, according to the 2019 Global 500 report issued by Brand Finance on 22 January 2019. Deloitte’s strong performance was due to higher scores in Brand Finance’s metrics of familiarity, consideration, satisfaction, preference, recommendation and revenue.
Washington, D.C.–based cybersecurity investment firm Strategic Cyber Ventures released its first annual report on The State of 2018 Cybersecurity Investing that includes some key findings about the DMV.
2019 has kicked off with a wave of innovative health care solutions highlighted at mega-conferences like CES and the J.P. Morgan Healthcare Conference – from the introduction of the first wearable blood pressure monitor to virtual home health care for seniors to online vision tests allowing patients to renew prescriptions from anywhere at anytime. We are truly living through an age of disruption spurred by technological advances.
United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Upon closing, United Therapeutics paid Arena $800 million. Arena is also entitled to potential milestone payments of up to $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products.
We need to chart a new course.